| 摘要 |
Use of a compound containing the effective therapeutically amount of at least a primary agent and an effective therapeutically amount of at least a co-agent, said primary agent containing a primary water soluble amino or related to the aminos derived from benzene acid in the molecular weight range which fluctuates between 100 and 1,400 daltons, to be used in the treatment in mammals that suffer from a neurological disease or its related physiologically symptomatology, wherein said primary agent and the combination of its co-agents serve to prevent the progression of said neurological disease or its related pathophysiologically symptomatology.
|
